Germany’s Fresenius in talks to buy generic drugmaker Akorn

April 7, 2017 (Reuters) – German healthcare group Fresenius SE & Co KGaA said on Friday that it was in talks with the generic drugmaker Akorn Inc for a potential takeover. Shares of Akorn, which has a market value of about $3.7 billion, were up 10 percent at $32.60 in aftermarket trading. There can be no assurance any transaction will result from these discussions, Fresenius said in a statement. Akorn confirmed the talks with Fresenius, whose businesses range from kidney dialysis and tube feeding equipment to running hospitals. Fresenius’s chief…

Read More